|1.||Mannaerts, Bernadette: 4 articles (07/2015 - 10/2010)|
|2.||Devroey, Paul: 3 articles (07/2012 - 10/2010)|
|3.||Devroey, P: 3 articles (12/2009 - 12/2004)|
|4.||Witjes, Han: 2 articles (07/2015 - 10/2010)|
|5.||Elbers, Jolanda: 2 articles (07/2015 - 08/2011)|
|6.||Leader, Arthur: 2 articles (07/2012 - 04/2012)|
|7.||Mannaerts, Bernadette M J L: 2 articles (04/2012 - 08/2011)|
|8.||Fauser, B C J M: 2 articles (12/2009 - 05/2009)|
|9.||Mannaerts, B M J L: 2 articles (12/2009 - 05/2009)|
|10.||Rosenwaks, Zev: 1 article (07/2015)|
|1.||Ovarian Hyperstimulation Syndrome
04/01/2012 - "In three studies of corifollitropin alfa treatment, we assessed all cases of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication of ovarian stimulation treatment. "
08/01/2011 - "In large, pooled analyses of clinical trials, the incidence of ovarian hyperstimulation syndrome in both the corifollitropin alfa and rFSH treatment arms was consistent with that expected in the relatively young patient population. "
07/01/2015 - "The incidence of serious adverse events was 0.4% versus 2.7% in the corifollitropin alfa and recombinant FSH groups, respectively, and of ovarian hyperstimulation syndrome (OHSS; all grades) was 1.7% in both groups. "
04/01/2012 - "Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH."
09/01/2010 - "Finally, corifollitropin alfa is well tolerated and is not correlated with serious adverse events, except for the slightly higher incidence of ovarian hyperstimulation syndrome compared with traditional management with recombinant FSH."
|2.||Body Weight (Weight, Body)
07/01/2010 - "Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women."
12/01/2009 - "The study population comprised 1506 treated patients with mean age of 31.5 years and body weight of 68.6 kg. Ongoing pregnancy rates of 38.9% for the corifollitropin alfa group and 38.1% for rFSH were achieved, with an estimated non-significant difference of 0.9% [95% confidence interval (CI): -3.9; 5.7] in favor of corifollitropin alfa. "
02/01/2013 - "Patients were aged ≤ 36 years and had a body weight >60 kg. The ongoing pregnancy rates per started cycle increased in the corifollitropin alfa and rFSH groups from 31.9 and 31.3%, respectively, in the lowest response group (0-5 oocytes) to 41.9 and 43.4% in the highest response group (>18 oocytes) with a significant linear trend (P = 0.04). "
08/01/2011 - "Clinicians treating IVF patients with corifollitropin alfa should alter their treatment paradigm as a lower or higher dose than recommended according to body weight does not affect the ovarian response, which depends mainly on the ovarian reserve. "
08/01/2011 - "Corifollitropin alfa doses based on body weight: clinical overview of drug exposure and ovarian response."
08/01/2011 - "In this multicentre, phase III uncontrolled trial, patients (>60 kg) started treatment with one injection of 150 µg corifollitropin alfa on cycle Day 2 or 3 of menses and 0.25 mg ganielix on stimulation Day 5 or 6. Primary outcome measures were antibody formation against corifollitropin alfa (using highly sensitive radioimmunoprecipitation assay), hypersensitivity reactions, local tolerance and adverse events (AEs). "
01/01/2012 - "Corifollitropin alfa for female infertility."
08/01/2011 - "Corifollitropin alfa: a new option to treat female infertility."
08/01/2001 - "Furthermore, the pharmacokinetic and dynamic profile of FSH-CTP may lead to the development of new, more convenient regimens for the treatment of male and female infertility."
04/01/2009 - "Thus, corifollitropin alfa has the potential to serve as a viable fertility agent and to gain a place in the infertility market."
04/01/2009 - "Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility."
12/01/2004 - "Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility."
04/01/2009 - "Corifollitropin alfa is being developed by Schering-Plough Corp as an injectable, long-acting follicle-stimulating hormone (FSH) agonist for the treatment of infertility. "
|2.||Follicle Stimulating Hormone (Follitropin)
|3.||Gonadotropin-Releasing Hormone (GnRH)